Return to search results.
Complete title: An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
|Research Study Number||20121498|
|Principal Investigator||Laura Chow|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- Men & women = to or > 18 years of age
- Subjects with histologically or cytologically-documented locally advanced non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection
- Disease recurrence or progression during/after one prior platinum-containing doublet chemotherapy regimen for advanced or metastatic disease
- Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status = to or < 1
- A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- Subjects with carcinomatous meningitis.
- Subjects with active, known or suspected autoimmune disease, or subjects with interstitial lung disease
- Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization
- Prior therapy with anti-programmed death-1 (anti-PD-1), anti programmed cell death ligand 1 (anti-PD-L1), anti programmed cell death ligand 2 (anti-PD-L2), anti-CD137, or anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Other exclusion criteria may apply.
Lung Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.